Risk of invasive fungal infections in patients with high‐risk MDS and AML receiving hypomethylating agents
- 3 April 2020
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 95 (7), 792-798
- https://doi.org/10.1002/ajh.25808
Abstract
Invasive fungal infections (IFI) are a significant source of morbidity and mortality for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Given the heterogeneity of the population receiving hypomethylating agents (HMA), it is difficult for clinicians to accurately assess their patients’ risk of infection. Literature on the incidence of IFI following HMA is limited to several studies of azacitidine. The primary objective of this retrospective study was to establish the incidence of IFI in HMA treated AML/MDS patients at a large U.S. comprehensive cancer center. Secondary objectives included comparing incidence of IFI among pre‐specified subgroups to identify potential risk factors for IFI. Two hundred three patients with AML, intermediate to very high risk MDS or chronic myelomonocytic leukemia who received at least two cycles of HMA were included. The incidence of IFI, as defined by the European Organization for Research and Treatment of Cancer / Invasive Fungal Infections Cooperative Group criteria, was 9.6%, with 20 IFI diagnosed following HMA (3 proven, 4 probable, 13 possible). Among the proven cases of IFI, molds included Scedosporium and Fusarium spp. Eleven patients who developed IFIs were neutropenic upon initiating HMA. The majority (17/20) of infections occurred during the first four cycles. Given this incidence, mold‐active prophylaxis can be considered in patients who are neutropenic at the start of therapy.This publication has 15 references indexed in Scilit:
- Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopeniaMedicine, 2018
- Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid LeukemiaJournal of Clinical Oncology, 2017
- Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemiaBlood, 2013
- Revised International Prognostic Scoring System for Myelodysplastic SyndromesBlood, 2012
- Infections in myelodysplastic syndromesHaematologica, 2012
- Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry studyHaematologica, 2009
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with NeutropeniaThe New England Journal of Medicine, 2007
- Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 2006